ALK Gene Fusions and ROS1Gene Fusions Detection Kit
For qualitative detection of 26 ALK gene fusions and 14 ROS1 gene fusions ALK gene fusions and ROS1 gene fusions define unique molecular subsets of non–small-cell lung cancer (NSCLC). EML4, KIF5B, TFG, KLC1 etc., are identified as fusion partners of ALK; SLC34A2, CD74, SDC4, EZR etc., are identified as fusion partners of ROS1.These fusions lead to constitutive kinase activity and activation of downstream pathways, leading to carcinogenesis.It has been reported that the presence of the ALK gene fusions and ROS1 gene fusions are correlated with the efficacy of TKI therapy.
Detection of ALK and ROS1 fusions in patients with advanced NSCLC indicates eligibility for treatment with ALK inhibitor crizotinib.
The AmoyDx® ALK Gene Fusions and ROS1 Gene Fusions Detection Kit is an in vitro nucleic acid amplification test intended for qualitative detection of 26 ALK gene fusions and 14 ROS1 gene fusions.
The kit is based on three major processes:
(1) Specimen preparation to isolate total RNA from NSCLC FFPE samples;
(2) Reverse transcription of the target RNA to generate complementary DNA (cDNA);
(3) Simultaneous PCR amplification of target cDNA and detection of ROS1 gene fusions with specific primers and fluorescent probes.
To order, please contact firstname.lastname@example.org.
AmoyDx ALK fusions and ROS1 fusions Detection Kit provides reagents to perform assays for 8 tests:
ALK fusions and ROS1 fusions Detection Kit